Details of the Drug Combination

General Information of Drug Combination (ID: DCSMB49)

• Drug Combination Name: RTB101 + Ridaforolimus
• Indication: Carcinoma; Status: Investigative [1]
• Component Drugs:
  RTB101 (DM62QTW): Small molecular drug
  Ridaforolimus (DMLHEU7): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: MDAMB436
  Zero Interaction Potency (ZIP) Score: 0.54
  Bliss Independence Score: 1.13
  Loewe Additivity Score: 4.13
  LHighest Single Agent (HSA) Score: 5.88

Molecular Interaction Atlas of This Drug Combination

Indication(s) of RTB101

Disease Entry	ICD 11	Status	REF
Respiratory tract infection	CA45	Phase 3	[2]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[3]

RTB101 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
CREB-regulated transcription coactivator 1 (TORC1)	TT4GO0F	CRTC1_HUMAN	Inhibitor	[5]

Indication(s) of Ridaforolimus

Disease Entry	ICD 11	Status	REF
Sarcoma	2A60-2C35	Phase 3	[4]

Ridaforolimus Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Serine/threonine-protein kinase mTOR (mTOR)	TTCJG29	MTOR_HUMAN	Inhibitor	[6]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Ewing sarcoma-peripheral primitive neuroectodermal tumour	DCG1N85	ES2	Investigative	[7]
Breast and ovarian cancer syndrome	DCDS03D	UWB1289	Investigative	[1]
Breast and ovarian cancer syndrome	DCXFJ3A	UWB1289+BRCA1	Investigative	[1]
Breast carcinoma	DCLQE0M	KPL1	Investigative	[1]
Breast carcinoma	DCL12U8	OCUBM	Investigative	[1]
Carcinoma	DCVCHPB	OV90	Investigative	[1]
Carcinoma	DC42M44	EFM192B	Investigative	[1]
Colon adenocarcinoma	DC32D75	LOVO	Investigative	[1]
Colon carcinoma	DCON33B	RKO	Investigative	[1]
Invasive ductal carcinoma	DCQBGAY	T-47D	Investigative	[1]
Rectal adenocarcinoma	DCB3AZD	SW837	Investigative	[1]
Adenocarcinoma	DCDAC43	CAOV3	Investigative	[8]
Adenocarcinoma	DCWQ8GD	OVCAR3	Investigative	[8]
Adenocarcinoma	DCNN60Y	A427	Investigative	[8]
Adenocarcinoma	DC633J4	NCIH1650	Investigative	[8]
Adenocarcinoma	DCK1RN6	NCIH2122	Investigative	[8]
Adenocarcinoma	DC11JDJ	NCIH23	Investigative	[8]
Adenocarcinoma	DC2FP5T	NCIH520	Investigative	[8]
Adenocarcinoma	DCAAG7Z	COLO320DM	Investigative	[8]
Adenocarcinoma	DCYA1NH	DLD1	Investigative	[8]
Adenocarcinoma	DC1JPKC	HT29	Investigative	[8]
Adenocarcinoma	DCI3XU5	SW-620	Investigative	[8]
Amelanotic melanoma	DCVFEF2	A2058	Investigative	[8]
Germ cell tumour	DC6B4WV	PA1	Investigative	[8]
Large cell lung carcinoma	DCVYWZH	NCI-H460	Investigative	[8]
Malignant melanoma	DCP24AP	A375	Investigative	[8]
Malignant melanoma	DCWP25P	HT144	Investigative	[8]
Malignant melanoma	DC7KTTZ	RPMI7951	Investigative	[8]
Malignant melanoma	DCJH8R6	SKMEL30	Investigative	[8]
Malignant melanoma	DCGTM6F	UACC62	Investigative	[8]
Mesothelioma	DCPKBCI	MSTO	Investigative	[8]
Non small cell carcinoma	DCH0RMP	SKMES1	Investigative	[8]
Ovarian endometrioid adenocarcinoma	DC6P8BI	A2780	Investigative	[8]
Ovarian serous cystadenocarcinoma	DCUA4QR	SK-OV-3	Investigative	[8]
Prostate carcinoma	DC1AMWS	VCAP	Investigative	[8]
Prostate carcinoma	DCD3KOO	LNCAP	Investigative	[8]

References

• [1] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
• [2] ClinicalTrials.gov (NCT04139915) Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT04409327) Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes. U.S. National Institutes of Health.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7884).
• [5] Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
• [6] A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
• [7] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [8] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.